// Biotech and Pharma Therapeutics
Lilly, J&J CEOs top pharma’s highest paid list—again
May 13, 2026 / Pharma CEO pay / GLP-1 market / Eli Lilly / Biopharma leadership / Obesity drug competition
Pharma CEO compensation rose sharply in 2025, led by Eli Lilly’s David Ricks amid GLP-1 market growth. Executive pay reflected obesity drug momentum, commercial performance, leadership transitions, and intensified competition across major biopharmaceutical companies.
India’s pharma industry is going global. But can it catch up to China?
May 13, 2026 / Indian pharma / Biopharma innovation / Global drug manufacturing / China pharma competition / Pharmaceutical infrastructure
India’s pharmaceutical industry is expanding globally through generics, manufacturing, and acquisitions, but experts say limited innovation infrastructure, capital, regulatory alignment, and clinical trial capabilities may delay its ability to rival China as a biopharma innovation leader.
Can Australia turn trial traffic into biotech value?
May 13, 2026 / Biotech clinical trials / Early-stage drug development / Australia biotech / Translational medicine / Global pharmaceutical research
Australia is emerging as a strategic hub for early-stage biotech trials, offering faster, lower-cost human studies that help companies generate credible clinical data efficiently, positioning the country as a valuable partner in global drug development and translational research.
Interactive AI model improves explainable lung cancer diagnosis from CT scans
May 12, 2026 / Lung cancer AI / CT scan diagnostics / Explainable artificial intelligence / Pulmonary nodule detection / Radiology decision support
Researchers developed an interactive AI model that improves explainable lung cancer diagnosis from CT scans by generating physician-like findings through question-and-answer interactions, enhancing transparency, diagnostic consistency, clinician training, and trust in AI-assisted pulmonary nodule evaluation.
Medtronic to close California site amid restructuring
May 11, 2026 / Medtronic restructuring / Cardiovascular devices / Interventional cardiology / Medical device industry / Healthcare operations strategy
Medtronic will close its California facility as part of a broader cardiovascular restructuring strategy, consolidating cardiac and interventional businesses to streamline operations, accelerate innovation, and strengthen long-term growth across cardiovascular and surgical care markets.
// 4th Industrial Revolution
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
May 13, 2026 / AI drug discovery / Biopharma acquisitions / Cell therapy innovation / Oncology therapeutics / Pharmaceutical investment
Biopharma activity accelerated with Assertio accepting a higher Zydus acquisition bid, Isomorphic Labs raising $2.1 billion for AI-driven drug discovery, and Kyverna advancing a potential first FDA-approved autoimmune cell therapy, highlighting continued momentum in oncology, AI, and immunology innovation.
Anomaly Insights Secures $17M to Scale AI Payer Intelligence for Health Systems
May 13, 2026 / Healthcare AI / Payer intelligence / Revenue cycle management / Claims analytics / Health system reimbursement
Anomaly Insights raised $17 million to expand its AI-powered payer intelligence platform, helping health systems identify denials, underpayments, and payer policy shifts in real time, improving revenue recovery, contract negotiations, and operational transparency across healthcare reimbursement workflows.
How self-driving networks are reshaping healthcare
May 13, 2026 / Healthcare AI networks / Autonomous infrastructure / Predictive network analytics / Digital health systems / Clinical IT automation
Self-driving healthcare networks use AI-driven automation, predictive analytics, and autonomous operations to improve clinical connectivity, reduce IT burden, strengthen cybersecurity, and support scalable digital care delivery across increasingly complex healthcare environments.
AI in MENA healthcare is not a single story
May 13, 2026 / Healthcare AI / MENA healthcare / Digital health innovation / AI healthcare infrastructure / Clinical technology adoption
AI adoption across Middle East and North Africa healthcare systems is accelerating, with regions pursuing distinct strategies shaped by infrastructure, regulation, and clinical priorities, creating a rapidly evolving landscape for scalable digital health and real-world healthcare innovation.
AI models predict sudden cardiac arrest risk using health records
May 13, 2026 / Sudden cardiac arrest / Artificial intelligence healthcare / Electronic health records / Electrocardiogram analysis / Predictive cardiology
Researchers developed AI models using electronic health records and electrocardiograms to identify individuals at elevated risk for sudden cardiac arrest, demonstrating the potential for earlier detection and preventive intervention in a condition with historically poor survival rates.
// Business & Markets
With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’
May 13, 2026 / Lexicon Pharmaceuticals / Novo Nordisk partnership / Diabetes drug development / Obesity therapeutics / Cardiometabolic innovation
Lexicon Pharmaceuticals is rebuilding around R&D innovation, supported by a $1 billion Novo Nordisk partnership, renewed diabetes ambitions, and pipeline advances in obesity, neuropathic pain, and cardiometabolic disease despite prior regulatory and commercial setbacks.
Artios teams up with GSK to evaluate alnodesertib
May 13, 2026 / Precision oncology / ATR inhibitor / Antibody-drug conjugate / Gastrointestinal cancer / Targeted cancer therapy
Artios Pharma and GSK are collaborating to evaluate the ATR inhibitor alnodesertib with GSK’s B7-H3-targeting antibody-drug conjugate in gastrointestinal cancers, advancing precision oncology strategies aimed at enhancing DNA damage response and targeted tumor therapy.
Rigel snaps up breast cancer drug Veppanu in up to $405m deal
May 13, 2026 / Breast cancer therapy / Oncology drug acquisition / Targeted cancer treatment / Hormone receptor-positive cancer / Pharmaceutical licensing deal
Rigel Pharmaceuticals acquired global rights to the newly approved breast cancer therapy Veppanu in a deal worth up to $405 million, signaling a major strategic expansion into oncology and targeted hormone receptor-positive breast cancer treatment.
Stryker values Amplitude Vascular purchase at up to $835M
May 12, 2026 / Intravascular lithotripsy / Peripheral arterial disease / Cardiovascular devices / Calcified plaque treatment / Medical device acquisition
Stryker acquired Amplitude Vascular Systems in a deal worth up to $835 million, expanding its cardiovascular portfolio with intravascular lithotripsy technology targeting complex peripheral arterial disease and calcified plaque management in vascular interventions.
Isomorphic raises $1.2bn for AI drug hunt
May 12, 2026 / AI drug discovery / Precision medicine / AlphaFold technology / Pharmaceutical innovation / Clinical development AI
Isomorphic Labs raised $1.2 billion to accelerate AI-driven drug discovery, expand its IsoDDE platform, and advance clinical candidates, reinforcing growing industry confidence in AI-enabled precision medicine and next-generation pharmaceutical R&D.
// Legal & Regulatory
Siemens Healthineers wins FDA clearance for 6 new interventional imaging systems
May 12, 2026 / Interventional imaging / FDA clearance / AI medical imaging / Cardiovascular procedures / Siemens Healthineers
Siemens Healthineers received FDA clearance for six AI-enabled interventional imaging systems designed to improve procedural precision, workflow efficiency, and image quality across cardiovascular and minimally invasive procedures through real-time deep-learning imaging optimization.
Artera gets FDA clearance for AI breast cancer risk prediction tool
May 12, 2026 / Breast cancer AI / Metastasis prediction / Histopathology imaging / Precision oncology / FDA-cleared diagnostics
Artera received FDA clearance for an AI-powered breast cancer risk tool that combines histopathology imaging with clinical data to identify patients at higher risk of distant metastases, supporting more personalized treatment and chemotherapy decision-making.
FDA’s leadership void leaves biotech with renewed ‘uncertainty’
May 13, 2026 / CAR-T therapy / Cell therapy / Diffuse large B-cell lymphoma / Immuno-oncology / South Korea biotech
Leadership instability at the FDA is creating renewed uncertainty for biotech companies, raising concerns about regulatory consistency, drug approval timelines, scientific oversight, and the future direction of innovation-friendly policies supporting rare disease and emerging therapies.
EC approves added indication for Pfizer’s Hympavzi
May 13, 2025 / Hemophilia treatment / Pfizer Hympavzi / Factor inhibitors / Rare blood disorders / European Commission approval
The European Commission expanded approval for Pfizer’s Hympavzi to include hemophilia A and B patients with inhibitors, offering adolescents and adults a new prophylactic treatment option aimed at reducing bleeding complications and improving long-term disease management.
Marty Makary’s Run as FDA Commissioner Is Over
May 12, 2026 / FDA leadership change / Marty Makary / Healthcare regulation / Public health policy / Drug regulatory uncertainty
Marty Makary resigned as FDA Commissioner after 13 months, intensifying uncertainty around U.S. regulatory leadership as the agency faces political pressure, pending budget scrutiny, and ongoing transitions affecting drug, food safety, and public health oversight.
// Research & Development
Takeda 0 for 4 against nausea and vomiting after axing another asset
May 13, 2026 / Takeda pipeline / Nausea treatment / Gastrointestinal therapeutics / Drug development setbacks / Supportive care medicine
Takeda discontinued another nausea and vomiting candidate, TAK-004, marking its fourth setback in the therapeutic area as the company reevaluates strategy despite ongoing unmet clinical need in gastrointestinal and supportive care treatments.
J&J launches improved Shockwave catheter
May 13, 2026 / Intravascular lithotripsy / Coronary artery disease / Calcified lesions / Cardiovascular intervention / Shockwave catheter
Johnson & Johnson launched the next-generation Shockwave C2 Aero catheter, enhancing intravascular lithotripsy treatment for complex calcified coronary lesions and improving physician flexibility in restoring arterial blood flow during cardiovascular interventions.
Penn researchers develop ApexGO to enhance promising antibiotic candidates
May 13, 2025 / AI antibiotic discovery / Antimicrobial resistance / Peptide therapeutics / Drug-resistant bacteria / Machine learning medicine
University of Pennsylvania researchers developed ApexGO, an AI-driven platform that optimizes antibiotic candidates by predicting effective molecular modifications, accelerating antimicrobial discovery and showing promising activity against drug-resistant bacteria in laboratory and animal studies.
Researchers find new way to deliver drugs directly into cancer cells
May 13, 2025 / Nanoparticle drug delivery / Cancer therapeutics / Mitochondrial targeting / Precision oncology / Gold nanoparticles
NUS researchers developed a DNA-barcoded nanoparticle platform that identifies drug carriers capable of targeting cancer cell mitochondria, significantly improving precision drug delivery and achieving substantial tumor regression in preclinical cancer models.
Scientists make old blood stem cells young again in major anti-aging breakthrough
May 12, 2025 / Anti-aging research / Blood stem cells / Regenerative medicine / Immune system aging / Cellular rejuvenation
Researchers reversed aging-related dysfunction in blood stem cells by restoring lysosomal balance, reducing inflammation, and improving healthy blood and immune cell regeneration, highlighting a promising pathway for anti-aging and regenerative medicine therapies.
// Politics
U.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changes
May 13, 2026 / Overdose deaths / Fentanyl crisis / Substance use disorder / Public health policy / Drug epidemic trends
U.S. overdose deaths declined for a third consecutive year in 2025, driven by reductions in fentanyl, cocaine, and methamphetamine fatalities, though experts remain concerned about evolving drug supply dynamics and future public health policy changes.
Two States Dominate Medical Device Exports
May 13, 2026 / Medical device exports / Medtech manufacturing / Healthcare supply chains / Medical innovation hubs / U.S. reshoring strategy
Minnesota and Tennessee emerged as the only U.S. states with medical devices as their top export, highlighting growing domestic medtech manufacturing strength, innovation ecosystems, and strategic positioning as healthcare companies accelerate supply chain reshoring and advanced device development.
Medicare halts enrollment of new hospice, home health providers
May 13, 2026 / Medicare fraud / Hospice care oversight / Home health agencies / CMS regulation / Healthcare compliance
CMS imposed a six-month moratorium on new hospice and home health provider enrollments to combat alleged Medicare fraud, reflecting broader federal efforts to strengthen oversight, protect vulnerable patients, and reduce improper healthcare spending.
New subpoena suggests DOJ has begun criminal investigation of gender-affirming care
May 13, 2026 / Gender-affirming care / DOJ investigation / Pediatric healthcare policy / Healthcare legal compliance / Federal grand jury subpoenas
Federal grand jury subpoenas issued to hospitals providing gender-affirming care to minors suggest the DOJ has escalated investigations into potential criminal enforcement, raising significant legal, ethical, and healthcare policy concerns for pediatric care providers nationwide.
EMA welcomes political agreement on Critical Medicines Act
May 13, 2026 / Critical Medicines Act / Pharmaceutical supply chain / Drug shortage prevention / European healthcare policy / Medicine access resilience
The EMA welcomed the EU’s provisional agreement on the Critical Medicines Act, aimed at strengthening medicine supply chain resilience, improving access to essential therapies, and reducing Europe’s vulnerability to pharmaceutical shortages and external manufacturing dependencies.